You have 9 free searches left this month | to do more

copanlisib

Copanlisib is a drug used to treat Anatomic Stage IV Breast Cancer AJCC v8, Follicular Lymphoma, Metastatic Breast Carcinoma, and other conditions. Copanlisib is being actively studied in 30 studies and prior, has been studied in 2.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)M D Anderson Cancer CenterJennifer Crombie
M.D. Anderson Cancer CenterDana-Farber Cancer InstituteBenedito A Carneiro, MD
Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer CenterChristian Buske
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Recruiting
  • Non Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center
2022-02-21
Feb 21, 2022
N
Recruiting
  • Follicular Lymphoma
  • +2 more
  • Rituximab
  • Copanlisib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
D
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
D
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
M
Not yet recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-31
Mar 31, 2022
D
Recruiting
  • Leukemia, Acute Lymphocytic
  • Copanlisib
  • Durham, North Carolina
    Duke Cancer Center
2021-07-19
Jul 19, 2021
H
Completed
  • Biliary Carcinoma
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-08-03
Aug 3, 2021
S
Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
2022-03-18
Mar 18, 2022
C
Active, not recruiting
  • HER2 Positive Breast Cancer
  • Cork, Ireland
  • +4 more
2021-10-08
Oct 8, 2021
M
Not yet recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-08-10
Aug 10, 2021
C
Recruiting
  • Follicular Lymphoma
  • Endometrial Cancer
  • Copanlisib
  • Ketogenic Diet
  • New York, New York
  • +2 more
2021-11-24
Nov 24, 2021
B
Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
  • +1 more
2021-11-18
Nov 18, 2021
N
Recruiting
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
C
Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Copanlisib
  • Nivolumab
  • Duarte, California
  • +2 more
2022-03-09
Mar 9, 2022
B
Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Beverly Hills, California
  • +5 more
2022-03-28
Mar 28, 2022
U
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Copanlisib
  • R-CHOP Chemotherapy
  • Aachen, Germany
  • +9 more
2021-10-19
Oct 19, 2021
U
Terminated
  • Lymphoid Leukemia
  • +3 more
  • Copanlisib
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021
M
Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
2022-03-28
Mar 28, 2022
M
Active, not recruiting
  • Mantle Cell Lymphoma (MCL)
  • Basking Ridge, New Jersey
  • +5 more
2021-04-14
Apr 14, 2021
N
Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Sacramento, California
  • +7 more
2022-03-25
Mar 25, 2022
C
Terminated
  • HER2-positive Breast Cancer
  • +3 more
  • Copanlisib
  • Trastuzumab emtansine
  • Cork, Ireland
  • +3 more
2020-12-14
Dec 14, 2020
J
Active, not recruiting
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-10-07
Oct 7, 2021
M
Recruiting
  • Thyroid Carcinoma
  • +5 more
  • I-124 PET/CT lesion dosimetry
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
2022-03-03
Mar 3, 2022
C
Withdrawn
  • Lymphoma, T-Cell
  • (no location specified)
2020-08-11
Aug 11, 2020